Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2023

Open Access 01-12-2023 | Syphilis | Research

Sexually transmitted infections and associated risk factors among the transgender population of Pakistan

Authors: Hasnain Javed, Abida Bano, Warda Fatima, Rimsha Khan, Asma Akhtar

Published in: BMC Infectious Diseases | Issue 1/2023

Login to get access

Abstract

Background

Transgender (TG) people are key drivers for sexually transmitted infections (STIs) all over the world. There is substantial evidence that STIs are associated with an increased likelihood of risky sexual behavior however little is known about the prevalence of STIs (HIV, HBV, HCV, and Syphilis) among HIV infected transgender population in Pakistan.

Methods

The current study investigated the seroprevalence of four STIs and associated socio-demographic risk factors among TGs of Punjab, Pakistan from July 2019 to June 2021. The samples were tested serologically and final confirmation was done through PCR for HIV, HBV, and HCV.

Results

A total of 1,562 transgenders cross-sectional descriptive records of the Punjab AIDS Control Program (PACP) were reviewed during the period from July 2019 to June 2021. The serological results evidenced that 533 (34.1%) had one pathogen, 309 (19.8%) had two or more (multiple) infections. The most predominant mono-infection among the transgender population was Syphilis 324 (20.7%) followed by HCV 114 (7.3%), HIV 69 (4.4%), and HBV 26 (1.7%). The highest proportions of Infections were found in TG residing in urban areas (68.6%) as compared to rural areas (31.4%). The seropositivity of all STIs was predominantly increased in Sex worker TGs i-e 55%, 46.5%, 38.5%, and 41.8% in HIV, HBV, HCV, and Syphilis respectively. Among 280 HIV-infected Transgender, 177 (63.2%) had Syphilis co-infections. While 87 (31%) and 47 (16.8%) HIV-infected individuals had HC and HBV co-infection respectively.

Conclusion

Transgender is neglected population group in society. All STIs were predominantly common among sex worker transgenders, Illiterate educational groups, and TGs residing in urban areas. There is a need to spread awareness about STIs, preventive strategies, and facilitation to health care programs in this high-risk population group.
Literature
1.
Bastos FI, Bastos LS, Coutinho C, Toledo L, Mota JC, Velasco-de-Castro CA, et al. HIV, HCV, HBV, and syphilis among transgender women from Brazil: assessing different methods to adjust infection rates of a hard-to-reach, sparse population. Med (Baltim). 2018;97(1S Suppl 1):16–24.CrossRef
2.
3.
Purohit A, Nayak P, Kapasi R, Harsh J, Singhi R. Webinar training – a panel discussion on ‘Hepatitis Free Future’ with elimination of Hepatitis by 2030. Indian J Public Health Res Dev. 2021;12:6–10.
4.
Tadvi J, Jaiswal NK, Sangani S, C J, Kishori R, Deshkar DW, et al. Seroprevalence of Hepatitis B and Hepatitis C infection’s in tertiary care hospital - dahod, Gujarat. Eur J Mol Clin Med. 2021;7:9115–21.
5.
Molla AA, Gelagay AA, Mekonnen HS, Teshome DF. Adherence to antiretroviral therapy and associated factors among HIV positive adults attending care and treatment in University of Gondar Referral Hospital, Northwest Ethiopia. BMC Infect Dis. 2018;18:266.CrossRefPubMedPubMedCentral
6.
Misir P. Introduction. In: Misir P, editor. HIV/AIDS and Adolescents: South Pacific and Caribbean. Singapore: Springer; 2019. pp. 1–20.CrossRef
7.
8.
Beale MA, Marks M, Cole MJ, Lee M-K, Pitt R, Ruis C, et al. Global phylogeny of Treponema pallidum lineages reveals recent expansion and spread of contemporary syphilis. Nat Microbiol. 2021;6:1549–60.CrossRefPubMedPubMedCentral
9.
10.
Van Gerwen OT, Jani A, Long DM, Austin EL, Musgrove K, Muzny CA. Prevalence of sexually transmitted infections and human immunodeficiency virus in Transgender Persons: a systematic review. Transgender Health. 2020;5:90–103.CrossRefPubMedPubMedCentral
11.
12.
Characterizing the Role of Intersecting Stigmas. and Sustained inequities in driving HIV Syndemics Across Low- and Middle-Income Settings - current opinions in HIV and AIDS. 2020; 15(4); 243.
13.
Poteat TC, Malik M, Beyrer C. Epidemiology of HIV, sexually transmitted infections, viral Hepatitis, and Tuberculosis among incarcerated Transgender People: a case of Limited Data. Epidemiol Rev. 2018;40:27–39.CrossRefPubMedPubMedCentral
14.
Thitipatarakorn S, Chinbunchorn T, Peelay J, Seekaew P, Amatavete S, Sangsai M, et al. Prevalence and the associated factors of hepatitis B and hepatitis C viral infections among HIV-positive individuals in same-day antiretroviral therapy initiation program in Bangkok, Thailand. BMC Public Health. 2022;22:144.CrossRefPubMedPubMedCentral
15.
Barbaric J, Bozicevic I, Manathunge A, Gajaweera C, Beneragama S. HIV, syphilis and hepatitis B prevalence, related risk behaviours and correlates of condom use among transgender women in two cities in Sri Lanka: findings from respondent-driven sampling surveys. Sex Health. 2021;18:311–8.CrossRefPubMed
16.
17.
18.
19.
King R, Nanteza J, Sebyala Z, Bbaale J, Sande E, Poteat T, et al. HIV and transgender women in Kampala, Uganda - double Jeopardy. Cult Health Sexuality. 2019;21:727–40.CrossRef
20.
Ong JJ, Baggaley RC, Wi TE, Tucker JD, Fu H, Smith MK, et al. Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure Prophylaxis for the Prevention of HIV infection: a systematic review and Meta-analysis. JAMA Netw Open. 2019;2:e1917134.CrossRefPubMedPubMedCentral
21.
Ganley KY, Wilson-Barthes M, Zullo AR, Sosa-Rubí SG, Conde-Glez CJ, García-Cisneros S, et al. Incidence and time-varying predictors of HIV and sexually transmitted infections among male sex workers in Mexico City. Infect Dis Poverty. 2021;10:7.CrossRefPubMedPubMedCentral
22.
Lucar J, Hart R, Rayeed N, Terzian A, Weintrob A, Siegel M, et al. Sexually transmitted infections among HIV-Infected individuals in the District of Columbia and estimated HIV Transmission Risk: Data from the DC Cohort. Open Forum of Infectious Diseases. 2018;5:ofy017.CrossRef
23.
Mayer KH, Allan-Blitz L-T. Similar, but different: drivers of the disproportionate HIV and sexually transmitted infection burden of key populations. J Int AIDS Soc. 2019;22:e25344. Suppl 6 Suppl Suppl 6.CrossRefPubMedPubMedCentral
24.
Hakim AJ, Iwamoto C, Badman SG, Willie B, Pekon S, Aeno H, et al. High prevalence of Chlamydia and Gonorrhea and the need for sexually transmitted infection testing among men who have sex with men and Transgender Women in Papua New Guinea. Sex Transm Dis. 2021;48:109–17.CrossRefPubMedPubMedCentral
25.
Assi A, Abu Zaki S, Ghosn J, Kinge N, Naous J, Ghanem A, et al. Prevalence of HIV and other sexually transmitted infections and their association with sexual practices and substance use among 2238 MSM in Lebanon. Sci Rep. 2019;9:15142.CrossRefPubMedPubMedCentral
26.
Del Romero J, García-Pérez JN, Espasa-Soley M. Prevention and treatment of sexually transmitted infections in high-risk individuals, including patients with HIV infection. Enferm Infecc Microbiol Clin (Engl Ed). 2019;37:117–26.PubMed
27.
Evens E, Lanham M, Santi K, Cooke J, Ridgeway K, Morales G, Parker C, Brennan C, de Bruin M, Desrosiers PC, Diaz X. Experiences of gender-based violence among female sex workers, men who have sex with men, and transgender women in Latin America and the Caribbean: a qualitative study to inform HIV programming. BMC Int Health Hum Rights. 2019;19:1–4.CrossRef
28.
Naeem F, Karellis A, Nair S, Routy JP, Yansouni CP, Kim J, Pai N. Multiplexed technologies for sexually transmitted infections: global evidence on patient-centered and clinical health outcomes. BMJ Global Health. 2021;6(7).
29.
Vernazza P, Rasi M, Ritzler M, Dost F, Stoffel M, Aebi-Popp K, Hauser CV, Esson C, Lange K, Risch L, Schmidt AJ. The Swiss STAR trial-an evaluation of target groups for sexually transmitted infection screening in the sub-sample of women. Swiss Med Wkly. 2020;150:w20393.CrossRefPubMed
30.
Hassan A, Agustin HGS, Burke L, Kofron R, Corado K, Bolan R, et al. Low incidence and prevalence of hepatitis C in two cohorts of HIV pre-exposure prophylaxis adherence interventions in men who have sex with men in Southern California. J Viral Hepatitis. 2022;29:529–35.CrossRef
31.
Zahra A, Saleem MA, Javed H, Khan MA. Prevalence of HCV-HIV co-infection with intravenous drug users in Central Punjab, Pakistan. Pak J Zool. 2021;54:2003–500.
32.
Thompson KA, Blank G, Toy J, Moore DM, Lachowsky N, Bacani N, et al. Prevalence and incidence of hepatitis C infection amongst men who have sex with men in a population-based pre-exposure prophylaxis program in British Columbia, Canada. Liver Int. 2022;42:1528–35.CrossRefPubMed
33.
Flores Anato JL, Panagiotoglou D, Greenwald ZR, Blanchette M, Trottier C, Vaziri M et al. Chemsex and incidence of sexually transmitted infections among canadian pre-exposure prophylaxis (PrEP) users in the l’Actuel PrEP Cohort (2013–2020). Sexually transmited infections. 2022;98:549–56.
Metadata
Title
Sexually transmitted infections and associated risk factors among the transgender population of Pakistan
Authors
Hasnain Javed
Abida Bano
Warda Fatima
Rimsha Khan
Asma Akhtar
Publication date
01-12-2023

Other articles of this Issue 1/2023

BMC Infectious Diseases 1/2023 Go to the issue

Research

Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China

Research

Nosocomial infections in the surgical intensive care unit: an observational retrospective study from a large tertiary hospital in Palestine

Research

Risk factors associated with Crimean-Congo hemorrhagic fever virus circulation among human, livestock and ticks in Mauritania through a one health retrospective study

Research

Genetic diversity of merozoite surface protein-5 (MSP-5) of Plasmodium vivax isolates from Malaria patients in Iran

Research

Healthcare utilization and adverse outcomes stratified by sex, age and long-term care residency using the Alberta COVID-19 Analytics and Research Database (ACARD): a population-based descriptive study

Research

Serological response to vaccination in post-acute sequelae of COVID
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits